Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

about

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

P2860

Q58765200-A9CB6C00-BDD7-49DF-8C7F-B90884D7BC7A

P2860

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q38712214

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dual targeting of MCL1 and NOX ...... tment of mantle cell lymphoma.

@en

type

Item

label

Dual targeting of MCL1 and NOX ...... tment of mantle cell lymphoma.

@en

prefLabel

Dual targeting of MCL1 and NOX ...... tment of mantle cell lymphoma.

@en

P1476

Dual targeting of MCL1 and NOX ...... tment of mantle cell lymphoma.

@en

P2093

Anna Esteve-Arenys

http://www.w3.org/2001/XMLSchema#string

Arnau Montraveta

http://www.w3.org/2001/XMLSchema#string

Elias Campo

http://www.w3.org/2001/XMLSchema#string

Elisabeth Höring

http://www.w3.org/2001/XMLSchema#string

German Ott

http://www.w3.org/2001/XMLSchema#string

Heiko van der Kuip

http://www.w3.org/2001/XMLSchema#string

Lea Schaaf

http://www.w3.org/2001/XMLSchema#string

Markus Kleih

http://www.w3.org/2001/XMLSchema#string

Matthias C Vöhringer

http://www.w3.org/2001/XMLSchema#string

Simon Heine

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.

The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.

Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.

Noxa: at the tip of the balance between life and death.

Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

P304

557-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14571

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

Dolors Colomer

Gaël Roué

P577

2017-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28295185

http://www.w3.org/2001/XMLSchema#string

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

about

P2860

P2860

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698